GAITHERSBURG, Md., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it is sponsoring the 35th National Veterans Wheelchair Games Business & Community Leaders’ Breakfast, co-presented by the Paralyzed Veterans of America (PVA) and the U.S. Department of Veterans Affairs (VA), taking place November 18, 2014 at Southern Methodist University in Dallas, Texas. This sponsorship marks the first in a series of initiatives reinforcing the Company’s commitment to the PVA and the members it serves.
The goal of the Business & Community Leaders’ Breakfast will be to provide awareness and support for the 35th National Veterans Wheelchair Games, which will be held June 21-26, 2015 in Dallas, Texas. Additionally, the PVA and VA will showcase the benefits and opportunities available to participating companies and organizations in Dallas as the host city for the games. Nuo Therapeutics will join business and community leaders from local, regional and national companies and organizations at the upcoming breakfast event to demonstrate its dedication to helping veterans of all ages challenge themselves to celebrate their abilities and to learn more about the largest annual wheelchair sporting event in the world, which brings together more than 600 veterans and approximately 3,000 volunteers from the community each year.
Martin Rosendale, Chief Executive Officer of Nuo Therapeutics, commented, “In the last 10 years, over 2.5 million veterans have returned to the United States following active deployment. A large number of those veterans have sustained life-altering injuries, many of them involving some form of paralysis. As a company involved in providing treatment options for chronic wounds, including pressure ulcers which commonly affect paralyzed individuals, we are thrilled to initiate our new relationship with the PVA by sponsoring the kick-off breakfast for the 2015 National Veterans Wheelchair Games and to support the amazing work this organization does for our paralyzed veterans.”
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company’s flagship product, Aurix™ is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds. For additional information please visit www.nuot.com or www.aurixsystem.com.
Safe Harbor Statement -- Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Nuo Therapeutics actual results may differ materially due to a number of factors, many of which are beyond Nuo Therapeutics’ ability to predict or control, the Company’s ability to successfully launch and rebrand its wound care system in the timeframe and to the extent anticipated, the Company’s ability to estimate the potential of the wound care market and to commercialize any of its rebranded products / therapies, successfully execute its Aurix (formerly AutoloGel) sales and commercialization strategies, the Company’s ability to launch Aurix as expected and derive financial and commercial benefits of such launch, to achieve Aurix expected reimbursement rates in 2014 and thereafter, the Company’s ability to comply with the debt covenants and restrictions under the existing loan facilities, the Company’s ability to realize expected benefits from the Arthrex licensing arrangement, the Company’s ability to collect the data necessary for the grant of the unconditional coverage, the Company’s ability to continue in its efforts to expand in the wound care market, its ability to successfully negotiate with physician offices as anticipated and to realize the anticipated sales growth from such treatments, the likelihood of a favorable CMS determination relating to the reimbursement rates for Aurix, to successfully realize sales of the Angel Technology resulting in the royalty stream to the Company, the Company’s ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company’s expectations of favorable future dialogue with potential strategic partners, and its ability to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company’s sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company’s ability to raise additional capital and to continue as a going concern, and Nuo Therapeutics’ ability to execute on its strategy to market the Aurix System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as “believes,” “forecasted,” “projects,” “is expected,” “remain confident,” “will” and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Nuo Therapeutics, Inc. Nuo Therapeutics operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Nuo Therapeutics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2013, the most recent Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2014, and other subsequent public filings. These filings are available at www.sec.gov.
CONTACT: Nuo Therapeutics, Inc. Martin Rosendale, CEO Steven Shallcross, EVP/CFO 240-499-2680 Investors / Media: The Ruth Group Lee Roth / Kirsten Thomas 646-536-7012 / 7014 lroth@theruthgroup.com / kthomas@theruthgroup.com
Help employers find you! Check out all the jobs and post your resume.
